182 related articles for article (PubMed ID: 9490144)
21. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
Reis LO; Denardi F; Faria EF; Silva ED
Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
[TBL] [Abstract][Full Text] [Related]
22. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
24. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study.
Bouchot O; Soret JY; Jacqmin D; Lahlou N; Roger M; Blumberg J
Horm Res; 1998; 50(2):89-93. PubMed ID: 9701702
[TBL] [Abstract][Full Text] [Related]
25. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
26. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
27. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
29. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
[No Abstract] [Full Text] [Related]
30. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.
Minkov NK; Zozikov BI; Yaneva Z; Uldry PA
Int Urol Nephrol; 2001; 33(2):379-83. PubMed ID: 12092661
[TBL] [Abstract][Full Text] [Related]
31. [Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate].
Richaud P; Salem N; Gaston R; Mauriac L; Chacon B; Bussières E
Cancer Radiother; 1998; 2(1):27-33. PubMed ID: 9749093
[TBL] [Abstract][Full Text] [Related]
32. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
33. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
Sharifi R; Knoll LD; Smith J; Kramolowsky E
Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
[TBL] [Abstract][Full Text] [Related]
34. Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
Sasagawa I; Kubota Y; Nakada T; Suzuki H; Hirano J; Sugano O; Kato H; Imamura A; Mastushita K; Onmura Y; Saito M; Adachi M
Int Urol Nephrol; 1998; 30(6):745-53. PubMed ID: 10195870
[TBL] [Abstract][Full Text] [Related]
35. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
37. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.
Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J
World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
39. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
Decensi A; Torrisi R; Fontana V
Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
[TBL] [Abstract][Full Text] [Related]
40. [Diferelin treatment of primary local and generalized cancer of the prostate].
Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
Urologiia; 2001; (6):17-9. PubMed ID: 11785073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]